Core Insights - Regentis Biomaterials Ltd. has announced the appointment of Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately [1] - GelrinC, the company's product for knee cartilage repair, has received CE Mark approval in Europe and is currently in the pivotal Phase III trial in the U.S. [1] Company Developments - The appointment of Ori Gon brings substantial experience in public company management, medtech, and capital markets to Regentis [1] - Regentis is focused on innovative tissue repair solutions within the regenerative medicine sector [1] Product Status - GelrinC is the only restorative product specifically designed for knee cartilage repair [1] - The product's CE Mark approval indicates regulatory acceptance in Europe, while the ongoing FDA Phase III trial represents a critical step for market entry in the U.S. [1]
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial